Immune Response Licensing Pharma Companies 
pharmaphorum
JANUARY 7, 2021
The California-based company has signed a non-exclusive license with Pfizer to supply its 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.
pharmaphorum
DECEMBER 21, 2020
It’s the first major partnership for Janux, which was set up in 2017, and could be the last to be organised by Merck’s R&D head Roger Perlmutter who is retiring from the big pharma company at the end of the year.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
SEPTEMBER 5, 2023
Investigation of the possibility of VAED is crucial during clinical trials for decision-making on vaccine licensing by regulatory agencies. Finally, addressing the time-consuming and costly transition from non-clinical to clinical development due to difficulties in predicting human immune responses is another issue.
pharmaphorum
NOVEMBER 23, 2021
Sanofi has bolstered its push into mRNA-based therapies with a new licensing deal – but not as might be expected with some up-and-coming biotech company. The post Chinese tech giant Baidu licenses mRNA algorithm to Sanofi appeared first on.
pharmaphorum
SEPTEMBER 23, 2021
AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19. VaxEquity said it has also received additional investment from Morningside Ventures – which provided seed funding for the company – in connection with the AZ alliance.
Roots Analysis
JANUARY 27, 2025
Moreover, protein-based drugs are also well tolerated inside the body, thereby reducing the chances of causing any immune response in the body. Such deals are inked to allow companies to expand their respective technology / product portfolios, and gain additional capabilities related to subcutaneous biologics.
Expert insights. Personalized for you.
53 
Let's personalize your content